Woburn, MA, November 26, 2007 - BioTrove, Inc. today announced that president and CEO Albert Luderer, Ph.D., will participate in the 19th Annual Piper Jaffray Health Care Conference in New York City on November 27. Following two global deals announced in the last three weeks - a marketing collaboration and licensing agreement with Applied Biosystems and a co-marketing agreement with Aglient - Dr. Luderer will provide an update on BioTrove's growth in the areas of drug discovery, genomic research and molecular diagnostics technology.

BioTrove is in the midst of significant growth, with the world's top pharmaceutical companies and academic institutions using BioTrove technology to enable groundbreaking research, stated Albert Luderer, Ph.D., president and CEO, BioTrove, Inc. Our recent deals are evidence of the value our technology provides to the life science, pharmaceutical and molecular diagnostics fields.

Following the recent BioTrove-Applied Biosystems collaboration, JP Morgan upgraded Applied Biosystems to overweight, citing key advantages of the BioTrove Open Array™ platform - including improved workflow and low sample requirements - as enhancing the value of Applied Biosystems' product.

Dr. Luderer's presentation will take place at 11:50 am on November 27.

About BioTrove, Inc.

BioTrove, Inc. offers two innovative technology platforms: RapidFire™, which enables the acceleration of drug discovery and pipeline decisions, and OpenArray™, which advances genomic research in a wide range of life science fields, including agriculture, disease research, bio-defense, and public health. With more than half of the world's ten largest pharmaceutical companies as clients, and partnerships with prestigious research and public health centers around the world, BioTrove's products and services ensure that an industry committed to accuracy and speed can meet business goals.

RapidFire™ Mass Spectrometry (RFMS) uses an innovative microfluidic technology to facilitate analysis at faster than 10 seconds per sample, eliminating the bottleneck created by traditional mass spectrometry throughput. RFMS is routinely used in many applications including the high-throughput screening of previously intractable drug targets, cytochrome P450 inhibition and other ADME assays and directed evolution studies.

The OpenArray™ Platform enables genomics researchers to generate SNP and real time qPCR data in the hundreds of thousands of data points per day, significantly increasing the number of samples analyzed while significantly decreasing the time and cost required. The flexible format and nanoliter scale of the OpenArray™ system allows for easy adjustment of sample and assay numbers, achieving economical, high-throughput genomics.

For more information, please visit www.biotrove.com or contact:

Applied Biosystems Forward Looking Statements

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as should, planned, and expect, among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These factors include but are not limited to: (1) rapidly changing technology and dependence on the development and customer acceptance of new products; (2) sales dependent on customers' capital spending policies and government-sponsored research; and (3) other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Applera does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

For Research Use Only. Not for use in diagnostic procedures. Practice of the patented 5' Nuclease Process requires a license from Applied Biosystems.

Applera, Applied Biosystems, and AB (Design) are registered trademarks of Applera Corporation or its subsidiaries in the U.S. and/or certain other countries. TaqMan is a registered trademark of Roche Molecular Systems, Inc.
Copyright © 2007. Applera Corporation. All rights reserved.

BioTrove, OpenArray, RapidFire, and the BioTrove logo are trademarks of BioTrove, Inc.
Copyright © 2007. BioTrove, Inc. All rights reserved.

Dr. Albert Luderer, President and CEO
BioTrove, Inc.
781-721-3648
info@biotrove.com

Arielle Bernstein
Makovsky + Company
212-508-9643
abernstein@makovsky.com